- Home
- TNXP vs REFI Comparison
TNXP vs REFI Comparison
Compare TNXP & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- REFI
- Stock Information
- Founded
- TNXP 2007
- REFI 2021
- Country
- TNXP United States
- REFI United States
- Employees
- TNXP N/A
- REFI N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- REFI Real Estate Investment Trusts
- Sector
- TNXP Health Care
- REFI Real Estate
- Exchange
- TNXP Nasdaq
- REFI Nasdaq
- Market Cap
- TNXP 213.7M
- REFI 255.6M
- IPO Year
- TNXP N/A
- REFI 2021
- Fundamental
- Price
- TNXP $18.12
- REFI $12.89
- Analyst Decision
- TNXP Buy
- REFI Strong Buy
- Analyst Count
- TNXP 1
- REFI 3
- Target Price
- TNXP $70.00
- REFI $20.00
- AVG Volume (30 Days)
- TNXP 734.4K
- REFI 129.9K
- Earning Date
- TNXP 11-07-2025
- REFI 11-04-2025
- Dividend Yield
- TNXP N/A
- REFI 15.98%
- EPS Growth
- TNXP N/A
- REFI N/A
- EPS
- TNXP N/A
- REFI 1.69
- Revenue
- TNXP $9,831,000.00
- REFI $54,287,847.00
- Revenue This Year
- TNXP $14.79
- REFI $11.43
- Revenue Next Year
- TNXP $933.49
- REFI $4.75
- P/E Ratio
- TNXP N/A
- REFI $7.61
- Revenue Growth
- TNXP N/A
- REFI N/A
- 52 Week Low
- TNXP $6.76
- REFI $12.00
- 52 Week High
- TNXP $130.00
- REFI $16.29
- Technical
- Relative Strength Index (RSI)
- TNXP 34.78
- REFI 46.23
- Support Level
- TNXP $18.53
- REFI $12.75
- Resistance Level
- TNXP $18.96
- REFI $13.12
- Average True Range (ATR)
- TNXP 1.05
- REFI 0.23
- MACD
- TNXP 0.39
- REFI 0.02
- Stochastic Oscillator
- TNXP 24.31
- REFI 27.69
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.